Attovia Therapeutics, Inc.
corporate_fare Company Profile
Attovia Therapeutics, Inc. (NASDAQ:ATTO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 8 items for ATTO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 8/10, with 5 rated 8 or above. Recent SEC coverage for ATTO spans 8-K, 10-Q, 4/A, 4.
Recent high-impact activity:
- Attovia Posts Q3 Loss of $22.3M With $395.9M Cash and Phase 2 Starts Set for 1H 2027
- Attovia's ATTO-1310 Holds 82% Itch Response at Week 12 After Single Dose
- Attovia Reports Q2 2026 Loss of $20.7M; IPO Proceeds Extend Runway into 2030
- Attovia's ATTO-1310 Shows Clinical Proof of Concept; Cash Runway Extended to 2030
- Director Colin Walsh's Amended Form 4 Reveals $12.5M Purchase and Previously Undisclosed Equity Swaps
Short Interest & Short Volume
4.50 days to coverFINRA reported short interest of 1,587,537 shares in ATTO as of the October 30, 2026 settlement, a 9.3% increase from the prior period — about 4.5 days to cover at its recent average daily volume. On November 20, 2026, 63.0% of ATTO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.